Background: Ocular medulloepithelioma (diktyoma) is a rare and potentially malignant paediatric tumour of the non-pigmented ciliary epithelium. Adjuvant chemotherapy can be given in advanced cases, but the indications and regimens remain to be defined. The aim was to identify whether adjuvant chemotherapy offers treatment benefit in advanced ocular medulloepithelioma.
Methods: This was a retrospective case series of subjects referred to a single specialist ocular oncology centre for advanced ocular medulloepithelioma subsequently treated with enucleation, including those needing adjuvant systemic vincristine, etoposide and carboplatin. A case-note review was performed for included subjects meeting referral criteria. The outcomes were histopathology characteristics, recurrence, metastases and survival.
Results: Between March 2010 and June 2017, four male patients (mean age 31 months) underwent enucleation for ocular medulloepithelioma. Adjuvant chemotherapy was commenced in 3 patients (75%) due to malignant histopathological features. With a mean follow-up time of 81.5 months (median 71 months, range 49-135 months) none of the patients have had recurrence, metastases or death from the tumour.
Conclusions: This series is unique in reporting the management of advanced malignant ocular medulloepithelioma with adjuvant systemic vincristine, etoposide and carboplatin for advanced tumours with malignant features. This regimen appears to be safe and may be effective in preventing metastatic spread.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10049972 | PMC |
| http://dx.doi.org/10.1038/s41433-022-01936-4 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Spectrum and demographic profile of pediatric intraocular tumors from a single center in India: an analysis of 445 eyes.
Graefes Arch Clin Exp Ophthalmol
December 2024
Department of Pediatric Retina & Ocular Oncology, Aravind Eye Hospital & Postgraduate Institute of Ophthalmology, Avinashi Road, Coimbatore, 641 014, Tamil Nadu, India.
Background: To describe the spectrum, demographic profile and distribution of intraocular oncology cases; both benign and malignant, in pediatric population in India.
Methods: It was a retrospective study done at a tertiary care hospital over a period of seven years (January 2015- December 2022) which included all the children aged 0-16 years, clinically diagnosed as intraocular tumors (benign or malignant) referred to our Ocular Oncology clinic. The data was retrieved from medical records department as well as electronic medical system (EMR) system.
Neuroendocrine and undifferentiated sinonasal and skull base tumors: An up-to-date narrative review.
Oral Maxillofac Surg
September 2024
2Nd Otolaryngology Department, "Attikon" University Hospital, National & Kapodistrian University of Athens, School of Medicine, Rimini 1, 12462, Chaidari, Athens, Greece.
Tumors located in the nasal cavity, paranasal sinuses and the skull base comprise a wide range of histologic subtypes. Among them, neuroendocrine and undifferentiated tumors are rare but noteworthy, because of their distinctive features, aggressive nature, and diagnostic complexities. A literature search was conducted in the PubMed/MEDLINE and the Scopus databases from 2019 until inception.
View Article and Find Full Text PDF[Clinical and prognostic analysis of opsoclonus-myoclonus-ataxia syndrome in children].
Zhonghua Er Ke Za Zhi
March 2024
Department of Neurology, Beijing Children's Hospital, Capital Medical University, National Center for Children's Health, Beijing 100045, China.
To summarize the clinical and prognostic features of children with opsoclonus-myoclonus-ataxia syndrome (OMAS). A total of 46 patients who met the diagnostic criteria of OMAS in the Department of Neurology, Beijing Children's Hospital from June 2015 to June 2023 were retrospectively analyzed. Centralized online consultations or telephone visits were conducted between June and August 2023.
View Article and Find Full Text PDFSuccessful use of tacrolimus for treatment-refractory neuroblastoma-associated opsoclonus-myoclonus-ataxia syndrome: A case series.
Pediatr Blood Cancer
April 2024
Department of Pediatrics, Ohio State University College of Medicine, Columbus, Ohio, USA.
Opsoclonus-myoclonus-ataxia syndrome (OMAS) is an autoimmune central nervous system disorder, primarily manifesting as a paraneoplastic sequalae to neuroblastoma, and characterized by motor disorders and behavioral disturbances. OMAS is typified by aberrant B-cell and T-cell activation. Current treatment involves immunosuppression using corticosteroids, intravenous immunoglobulin, and rituximab.
View Article and Find Full Text PDFMalignancies with a tendency to metastasize to the eyelid or ocular structures.
Clin Dermatol
July 2024
Department of Dermatology, University of Connecticut School of Medicine, Farmington, Connecticut, USA. Electronic address:
Metastatic tumors to the eye and eyelid are generally seen in patients with disseminated metastases in the setting of advanced disease. Occasionally, they can present as the first sign of occult malignancy. The choroid is the most common site of intraocular metastases secondary to its dense vascular supply.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!